The N-MOmentum pivotal trial (NCT02200770) is the largest phase 3 clinical trial in NMOSD and the only phase 3 trial that collected MRI data, which was incorporated into its attack adjudication ...

Roche is two for two in its phase 3 trials programme for satralizumab in the rare disease neuromyelitis optica spectrum disorder (NMOSD), setting up regulatory filings. The interleukin-6-targeting ...

NMOSD Patients At Greater Risk of Type 2 Diabetes A recent analysis found an elevated risk of type 2 diabetes among patients with neuromyelitis optica spectrum disorder, with steroid use possibly ...

A swift and accurate diagnosis is crucial when treating any disease, but especially a rare one. Sadly, people with particularly rare diseases that present like more recognisable conditions face a ...